Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.37 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.36 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.36 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.36 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.36 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.36 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.36 |
| ▸ | DAO | P14920 | 2/20 | 0.35 |
| ▸ | TRPV3 | Q8NET8 | 5/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.34 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.34 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.34 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.34 |
| ▸ | TKT | P29401 | 1/20 | 0.34 |
| ▸ | MTOR | P42345 | 2/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL336320 | 0.82 | TRPV4 (0.52) | TRPV4KCNH2TRPV1DAOPIK3CA | |
| SCHEMBL3686975 | 0.82 | TRPV4 (0.52) | TRPV4KCNH2TRPV1DAOTRPV3 | |
| SCHEMBL29417132 | 0.82 | TRPV4 (0.52) | TRPV4KCNH2TRPV1DAOPIK3CA | |
| SCHEMBL27774169 | 0.79 | TRPV4 (0.46) | TRPV4KCNH2TRPV1DAOTRPV3 | |
| SCHEMBL7992493 | 0.78 | TRPV4 (0.52) | TRPV4KCNH2TRPV1DAOPIK3CA | |
| Hydrochloric Acid SCHEMBL28558707 | 0.78 | TRPV4 (0.52) | TRPV4KCNH2TRPV1DAOPIK3CA | |
| SCHEMBL122387 | 0.78 | TRPV4 (0.52) | TRPV4KCNH2TRPV1DAOTRPV3 | |
| SCHEMBL1146016 | 0.77 | TRPV4 (0.47) | TRPV4KCNH2PSEN1PSEN2APH1B | |
| SCHEMBL13365250 | 0.77 | TRPV4 (0.47) | TRPV4KCNH2TRPV1DAOTRPV3 | |
| SCHEMBL1145546 | 0.77 | TRPV4 (0.47) | TRPV4KCNH2TRPV1DAOTRPV3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104169281-A | Fused pyrroledicarboxamides and their use as pharmaceuticals | SANOFI SA | 2014-11-26 | — | — | CN | claimed |
| CN-104169281-A | Fused pyrroledicarboxamides and their use as pharmaceuticals | SANOFI SA | 2014-11-26 | — | — | CN | disclosed |
| US-8288371-B2 | Ortho pyrrolidine, benzyl-substituted heterocycle CCR1 antagonists for autoimmune diseases and inflammation | PHARMACOPEIA, LLC (US) | 2012-10-16 | — | — | US | disclosed |
| WO-2009082526-A2 | ORTHO PYRROLIDINE, BENZYL-SUBSTITUTED HETEROCYCLE CCR1 ANTAGONISTS FOR AUTOIMMUNE DISEASES & INFLAMMATION | PHARMACOPEIA, INC. (US) | 2009-07-02 | — | — | WO | disclosed |
| US-20090093472-A1 | ORTHO PYRROLIDINE, BENZYL-SUBSTITUTED HETEROCYCLE CCR1 ANTAGONISTS FOR AUTOIMMUNE DISEASES & INFLAMMATION | PHARMACOPEIA, INC. (US) | 2009-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093472-A1 | ORTHO PYRROLIDINE, BENZYL-SUBSTITUTED HETEROCYCLE CCR1 ANTAGONISTS FOR AUTOIMMUNE DISEASES & INFLAMMATION | CCR1, CCR4, CCR3 | TRPV4 230/4885KCNH2 1755/4885PSEN1 3121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.